Qol Medical, LLC completed its acquisition of Evoke Pharma Inc on 2025-12-17, according to the Form 8-K Evoke Pharma Inc filed with the SEC on 2025-12-17. The filing's Item 2.01 states no aggregate dollar price. Evoke Pharma Inc filed the report because the deal made it part of Qol Medical, LLC.
| Acquirer | Qol Medical, LLC |
|---|---|
| Acquired | Evoke Pharma Inc |
| Completed | 2025-12-17 |
| Reported by | Evoke Pharma Inc (EVOK), the company acquired |
| Filing | Form 8-K, filed 2025-12-17 |
Want the whole picture on Qol Medical, LLC?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Qol Medical, LLC: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Qol Medical, LLC covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What the filing says
Parent completed the acquisition of the Company on December 17, 2025, by causing Merger Sub to merge with and into the Company (the "Merger") pursuant to the Merger Agreement without a vote of the Company stockholders in accordance with Section 251(h) of the General Corporation Law of the State of Delaware (the "DGCL").
More from the filing
As previously disclosed, Evoke Pharma, Inc. (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement"), with QOL Medical, LLC ("Parent") and Parent's wholly owned subsidiary, QOL-EOS Merger Sub, Inc. ("Merger Sub"), on November 3, 2025.
Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, on November 17, 2025, Merger Sub commenced a tender offer (the "Offer") to purchase all of the outstanding shares of common stock, par value $0.0001 per share, of the Company (the "Company Shares"), for $11.00 in cash per Company Share, without interest and subject to any withholding of taxes required by applicable legal requirements (the "Offer Price").
The Offer and related withdrawal rights expired as scheduled at one minute after 11:59 p.m., New York time, on December 15, 2025 (such date and time, the "Expiration Time"), and the Offer was not extended.
Quoted from Evoke Pharma Inc's Form 8-K.
This is the only completed acquisition Qol Medical, LLC reported under Item 2.01 in the last twelve months, as far as the filings of the companies it bought show.
Who runs it now, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Qol Medical, LLCLook up Qol Medical, LLC and see what is on record before you decide.
Get the free SnapshotWhere this comes from
A public company must file a current report on Form 8-K with the SEC within four business days of completing a significant acquisition or disposition of assets, under Item 2.01 of the report. The acquired company sometimes files one too, when the deal makes it a subsidiary of the buyer.
Every fact on this page is taken from one of those filings and linked to it: which company acquired which, the date the filing gives for completion, and the price when the filing states one in dollars, shown next to the sentence that states it. A filing states what was bought and on what terms; it rarely states why, and neither does this page.